Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2139820 | 1.00 | TACR1 (0.77) | TACR1 | |
| SCHEMBL9387393 | 0.87 | TACR1 (0.81) | TACR1 | |
| SCHEMBL8203286 | 0.87 | TACR1 (0.81) | TACR1 | |
| SCHEMBL8101033 | 0.85 | TACR1 (0.78) | TACR1 | |
| SCHEMBL8197471 | 0.85 | TACR1 (1.00) | TACR1 | |
| SCHEMBL8197474 | 0.85 | TACR1 (1.00) | TACR1 | |
| SCHEMBL8109904 | 0.85 | TACR1 (0.82) | TACR1 | |
| SCHEMBL8109903 | 0.85 | TACR1 (0.82) | TACR1 | |
| SCHEMBL7847110 | 0.84 | TACR1 (1.00) | TACR1 | |
| SCHEMBL6827800 | 0.84 | TACR1 (1.00) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092735-A1 | Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome | FARBER LOTHAR (DE) | 2003-05-15 | — | — | US | disclosed |
| US-6258800-B1 | Prodrugs of benzofuranylethyl carbamate NK1 antagonists | WARNER-LAMBERT COMPANY | 2001-07-10 | — | — | US | disclosed |
| EP-1075472-A1 | PRODRUGS OF BENZOFURANYLMETHYL CARBAMATE NK 1? ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999052903-A1 | PRODRUGS OF BENZOFURANYLMETHYL CARBAMATE NK1 ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092735-A1 | Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome | TACR1, NPSR1, NPFFR1 | TACR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.